Led · Equity · Aug 2025

Anocca develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies using a proprietary discovery engine and programmable human cells. Its lead programme, VIDAR-1, is the first non-viral gene-edited TCR-T cell therapy in Europe and targets mutant KRAS in pancreatic ductal adenocarcinoma. The company operates an in-house cGMP manufacturing and process development facility in Södertälje, Sweden and runs a custom software ecosystem called AnoccaOS. Anocca says it has the broadest pipeline of TCR-T oncology cell therapy treatments and a team of 130+ staff from 40+ nations. The company plans to use new financing to drive VIDAR-1 through early-stage clinical development and to advance its preclinical pipeline. Phase I recruitment for VIDAR-1 is open at university hospitals across Sweden, Denmark, Germany and the Netherlands. Anocca AB develops cancer cell therapies using proprietary analytical methods to identify and produce tumour-specific T-cells and matching T-cell receptors (TCRs). The company has automated its research platform and aims to manufacture TCR-T therapies on an industrial scale. Operations and manufacturing are located at former AstraZeneca facilities in Södertälje, Sweden. Anocca plans to use the new capital to expand research, development, and manufacturing capabilities and to progress its first products into clinical trials, with a first clinical trial planned to be initiated in 2024. Founded in 2014 and led by CEO Reagan Jarvis, the company employs about 100 people. Including the current raise, Anocca has received SEK 1.3 billion in venture capital and in December 2022 secured a EUR 25M venture debt facility from the European Investment Bank. Anocca engineers next-generation T-cell immunotherapies and is building libraries of novel T-cell therapies targeting difficult-to-treat solid tumours. The company intends to move its T-cell immunotherapies into clinical trials in a solid-tumour indication and aims to enter clinical trials in 2024. Alongside its oncology programs, Anocca's proprietary technologies are being applied to the development of vaccines and treatments for autoimmune diseases. Led by CEO Reagan Jarvis and founded in 2014, the company is based in Södertälje, Sweden. Financially, Anocca has previously raised €100 million from leading Nordic investors and recently secured additional financing to advance its pipeline. The new funds are intended to support progression of its programs toward clinical development. Anocca develops TCR‑modified T‑cell (TCR‑T) therapies using a proprietary, industrialised analytical cell biology platform that replicates human T‑cell biology in the laboratory. Its platform combines proprietary cell biology and molecular genetics technologies with integrated information management and bioinformatic software tools to enable scalable, high‑precision analysis. The company has generated a broad pipeline of TCR‑T assets targeting multiple antigen classes, including shared tumour targets, cancer-driving mutations and oncogenic viruses. Anocca operates an in‑house cGMP clinical manufacturing and process development facility and emphasises automation and software to drive multiple clinical programmes in parallel. The company plans to use the financing to accelerate its oncology pipeline into Phase I/IIa clinical trials and to bolster its in‑house manufacturing capabilities. Anocca was founded in 2014 and employs over 65 people at its Södertälje, Sweden site.

Led · Equity · Sep 2022

I-Phyc is a Birmingham-based green water treatment company that develops nature-based wastewater treatment solutions using algae. Its core system removes phosphorus, ammonia and other contaminants while locking away carbon and creating sustainable by-products from the biomass. The technology is already deployed at plants in Weston-super-Mare and Broadwindsor and is slated for a new installation at Croxton Kerrial. The company intends to use newly raised funds to establish itself as the technological leader in circular wastewater treatment solutions. I-Phyc has seen a major increase in enquiries over the past year and is in discussions with all major UK water companies as well as operators in the US and Scandinavia. The business currently employs 15 staff, operates a laboratory in Bristol, and plans to add five jobs in the next six months; it raised £2.3M in the reported funding round. I-Phyc develops a chemical-free water-treatment system that uses microalgae and cutting-edge technology to remove phosphorus, ammonia and other contaminants while locking away carbon and creating sustainable by-products such as biomass. The system is already installed and operating at a number of sites and the company says it is in discussions with all other major operators. The latest funding is intended to support roll-out at more municipal water plants and to aid internationalisation. I-Phyc employs 15 staff across its headquarters in Birmingham and a laboratory in Bristol. The raise comes as regulators introduce stricter limits on phosphorus and other contaminants, increasing demand for nature-based, lower-carbon solutions. To date the company has raised over £2m. Industrial Phycology has developed an eco-friendly wastewater treatment system that uses algae to remove nutrients such as phosphorus and nitrogen from sewage and wastewater. The recovered algal biomass can be used to generate biogas or fertiliser, and the process captures and retains carbon emissions to help reduce operators' carbon footprints. The company has completed a trial with Wessex Water at Avonmouth sewage works and is demonstrating the technology at a plant in Weston-super-Mare. Laboratories are based in Bristol and the company recently established new headquarters in Birmingham, where it is creating 19 new jobs. Industrial Phycology intends to use the funds to build its team in Birmingham and to launch its new system.